logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Regeneron Stock Is Soaring

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals ( REGN ) stock outperformed last week gaining over $27. The stock’s soaring was not the outcome of the market’s outperformance, for several consecutive days, but because the firm has announced great news...

Read More

February 10, 2020

0

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc ( ANVS ) , a clinical-stage drug platform company. This firm's focus is the treatment of neurodegenerative diseases. Annovis Bio Inc announced today new results from a double-blind, placebo-controlled study of...

Read More

May 21, 2021

0

Cassava Sciences Has Good News from Alzheimer's Disease Trial. See Also: Theravance Biopharma

Cassava Sciences From   NEWSWIRE  we learned that Cassava Sciences ( SAVA ) , a clinical-stage biotechnology company focusing on Alzheimer’s disease, announced that The Journal of Prevention of Alzheimer’s Disease ( JPAD ), a peer-reviewed journal for the research community, has published...

Read More

February 12, 2020

0

Aslan Pharmaceuticals: A Small Firm with Early, Promising Results for Atopic Dermatitis

Aslan Pharmaceuticals  Aslan Pharmaceuticals ( ASLN ) is a clinical-stage immunology company announced positive interim unblinded data from three dose cohorts of its ongoing randomized, double-blind placebo-controlled multiple ascending dose study of ASLAN-004 for moderate to severe atopic dermatitis.  ...

Read More

March 1, 2021

0

BridgeBio Pharma Has Promising News

BridgeBio Pharma Granted Fast Track Designation for Encaleret BridgeBio Pharma ( BBIO ) announced the U.S. FDA granted Fast Track designation for Encaleret – a treatment of autosomal dominant hypocalcemia ( ADH1 ), on World Hypoparathyroidism Awareness Day, an annual...

Read More

June 2, 2021

0

The Reasons Why Ovid Therapeutics' Stock Outperformed Today

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales Potential first-in-class therapy reduced...

Read More

March 3, 2021

0

Regeneron and Moderna Are Both Outperforming Today

Regeneron, Moderna, and COVID-19 The spread of COVID-19 , minute creatures that seem to be trying to defeat us, has been accused of bringing the market down over 1000 points yesterday. Investors who love the biotech stocks they carefully and...

Read More

February 25, 2020

0

Intellia Therapeutics Gene Editing Product NTLA-2001 - A Dream on its Way to Becoming Reality

Focus on Intellia Therapeutics Upcoming Presentation for NTLA-2001 Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June 26 Intellia Therapeutics NTLA-2001 for People Living with...

Read More

June 4, 2021

0

The FDA Lifts the Clinical Holds on bluebird bio Gene Therapies in Clinical Trials

Clinical Holds on bluebird bio Gene Therapies were Lifted by the FDA The U.S. FDA has lifted the clinical holds on the bluebird bio ( BLUE ) Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell...

Read More

June 7, 2021

0

More About Moderna, Gilead and Forty Seven

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna ( MRNA ) has accomplished that job and delivered it to the health authorities to decide upon the...

Read More

February 28, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 112
  • 113
  • 114
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy